Gossamer Bio Stock Forecast, Price & News

Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

Is Gossamer Bio a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Gossamer Bio stock.
View analyst ratings for Gossamer Bio or view top-rated stocks.

How has Gossamer Bio's stock price been impacted by COVID-19 (Coronavirus)?

Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GOSS shares have increased by 2.4% and is now trading at $10.84.
View which stocks have been most impacted by COVID-19.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Gossamer Bio.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.02. During the same quarter in the prior year, the company posted ($0.80) earnings per share.
View Gossamer Bio's earnings history.

What price target have analysts set for GOSS?

5 brokers have issued 12 month price objectives for Gossamer Bio's shares. Their forecasts range from $16.00 to $26.00. On average, they anticipate Gossamer Bio's share price to reach $22.50 in the next twelve months. This suggests a possible upside of 107.6% from the stock's current price.
View analysts' price targets for Gossamer Bio or view top-rated stocks among Wall Street analysts.

Who are Gossamer Bio's key executives?

Gossamer Bio's management team includes the following people:

• Faheem Hasnain, Chairman, President & Chief Executive Officer
• Bryan Giraudo, Chief Operating & Financial Officer
• Richard Aranda, Chief Medical Officer
• Laura Carter, Chief Scientific Officer (LinkedIn Profile)
• Christian Waage, Secretary, General Counsel & Executive VP

Who are some of Gossamer Bio's key competitors?

Some companies that are related to Gossamer Bio include Cytokinetics (CYTK), Intra-Cellular Therapies (ITCI), Insmed (INSM), Galapagos (GLPG), Reata Pharmaceuticals (RETA), ACADIA Pharmaceuticals (ACAD), Arcus Biosciences (RCUS), Cryoport (CYRX), Hypera (HYPMY), Amicus Therapeutics (FOLD), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Schrödinger (SDGR), Ligand Pharmaceuticals (LGND) and OPKO Health (OPK).
View all of GOSS's competitors.

What other stocks do shareholders of Gossamer Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA).

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.06%), Boxer Capital LLC (3.22%), Emerald Mutual Fund Advisers Trust (2.08%), Emerald Advisers LLC (1.99%), Geode Capital Management LLC (1.31%) and Goldman Sachs Group Inc. (0.75%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Jakob Dupont, Laura Carter, Luisa Salter-Cid and Waage Christian.
View institutional ownership trends for Gossamer Bio.

Which major investors are selling Gossamer Bio stock?

GOSS stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Boxer Capital LLC, Millennium Management LLC, BlackRock Inc., Royal Bank of Canada, Rafferty Asset Management LLC, and Nisa Investment Advisors LLC. Company insiders that have sold Gossamer Bio company stock in the last year include Bryan Giraudo, Laura Carter, and Luisa Salter-Cid.
View insider buying and selling activity for Gossamer Bio or view top insider-selling stocks.

Which major investors are buying Gossamer Bio stock?

GOSS stock was acquired by a variety of institutional investors in the last quarter, including Wolverine Asset Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Eversept Partners LP, Moore Capital Management LP, Schonfeld Strategic Advisors LLC, Geode Capital Management LLC, and Cubist Systematic Strategies LLC. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, and Waage Christian.
View insider buying and selling activity for Gossamer Bio or or view top insider-buying stocks.

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $10.84.

How much money does Gossamer Bio make?

Gossamer Bio has a market capitalization of $828.87 million. The company earns $-243.36 million in net income (profit) each year or ($3.26) on an earnings per share basis.

How many employees does Gossamer Bio have?

Gossamer Bio employs 196 workers across the globe.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is www.gossamerbio.com.

Where are Gossamer Bio's headquarters?

Gossamer Bio is headquartered at 3013 SCIENCE PARK, SAN DIEGO CA, 92121.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 684-1300 or via email at [email protected].